Frank Mccormick - Jun 21, 2024 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
/s/ Brian C. Stephenson, Attorney-in-Fact
Stock symbol
BBIO
Transactions as of
Jun 21, 2024
Transactions value $
$0
Form type
4
Date filed
6/25/2024, 05:39 PM
Previous filing
Dec 28, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BBIO Common Stock 120K Jun 21, 2024 Direct F1
holding BBIO Common Stock 980K Jun 21, 2024 By The Francis P. McCormick Rev Trust U/A DTD 1/27/2017 F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (Right to Buy) Award $0 +26K $0.00 26K Jun 21, 2024 Common Stock 26K $27.36 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Excludes 352,290 shares that were previously held directly by the Reporting Person and were transferred to the Reporting Person's trust account on April 16, 2024.
F2 Includes 352,290 shares that were previously held directly by the Reporting Person and were transferred to the Reporting Person's trust account on April 16, 2024.
F3 One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer.